Immune Thrombocytopenia (ITP)

What Is Immune Thrombocytopenia (ITP)?

Immune thrombocytopenia (ITP) is an autoimmune condition in which your immune system mistakenly destroys platelets — the blood cells that help your blood clot and stop bleeding. This leads to a lower-than-normal platelet count, which can cause easy bruising, prolonged bleeding, and sometimes spontaneous bleeding into the skin or other tissues.

ITP was previously called idiopathic thrombocytopenic purpura, but the name changed once it became clear that the cause is immune-mediated rather than unknown. "Purpura" refers to the purple-colored bruises or spots on the skin that can appear when platelet counts are low. Most people now simply say "immune thrombocytopenia" or "ITP."

ITP can affect people of all ages. In children, it often starts suddenly after a viral infection and usually resolves on its own within weeks or months. In adults, it tends to be more chronic, lasting six months or longer, and may require ongoing monitoring and treatment. In short: in children, ITP usually gets better; in adults, it is more likely to be long-term.

Many people with ITP are able to live normal, active lives, especially when their platelet counts are monitored and their treatment is tailored to their situation.

Important: This article is for general educational purposes only and does not replace personalized medical advice from your healthcare provider. Always discuss your diagnosis and treatment options with your doctor.

Key Facts About ITP

ITP is an autoimmune cause of low platelets, which can increase bleeding risk
Many cases in children resolve on their own without treatment
Adults often have chronic ITP but can usually be managed effectively
Treatments range from monitoring only to medicines and, in some cases, surgery

Types of ITP

Doctors classify ITP by cause (primary vs secondary) and duration (acute, persistent, chronic).

Primary ITP

Primary ITP has no identifiable underlying cause. The immune system produces antibodies — usually directed against proteins on the platelet surface such as glycoproteins IIb/IIIa — that mark platelets for destruction, primarily in the spleen.

Secondary ITP

Secondary ITP occurs in the context of another condition that drives immune dysregulation. Common underlying causes include:

Systemic lupus erythematosus (SLE)
Antiphospholipid syndrome
Chronic lymphocytic leukemia (CLL)
HIV, hepatitis C, or Helicobacter pylori infection
Certain medications

Acute vs Chronic ITP

Acute ITP: Lasts fewer than three months; most common in children
Persistent ITP: Lasts three to twelve months
Chronic ITP: Lasts more than twelve months; more common in adults

Symptoms of ITP

Many people with mild ITP have no symptoms at all and are diagnosed incidentally through a routine blood test. When symptoms do occur, they are related to the increased bleeding tendency caused by low platelet counts.

Common symptoms include:

Skin changes: easy or unexplained bruising, petechiae (tiny flat red or purple spots, often on the lower legs), and purpura (larger purple or red patches caused by bleeding under the skin)
Prolonged bleeding from minor cuts or injuries
Bleeding gums or nosebleeds that are difficult to stop
Heavy or prolonged menstrual bleeding
Blood in urine (pink or red-tinged) or stool (dark or tarry, which can suggest hidden bleeding)

Symptoms That Require Urgent Medical Attention

Serious bleeding is uncommon, but you should know the warning signs. Seek immediate medical care if you experience:

Sudden severe headache
Neurological symptoms such as confusion, vision changes, or weakness
Blood in vomit
Very heavy bleeding that does not stop
Signs of internal bleeding such as abdominal pain, dizziness, or rapid heartbeat

If you are unsure whether a symptom is serious, seek medical advice immediately.

Causes and Risk Factors

In primary ITP, the immune system produces antibodies that attach to platelets and mark them for destruction, primarily in the spleen. The bone marrow may attempt to compensate by producing more platelets — which is why mean platelet volume (MPV) is often elevated in ITP, as newly released platelets are naturally larger than older, mature ones.

The exact trigger for this autoimmune response is not fully understood, but several factors are associated with increased risk:

Recent viral infection (particularly in children)
Female sex (women are more commonly affected in the chronic adult form)
Pregnancy
Other autoimmune conditions such as lupus or rheumatoid arthritis
Certain infections including HIV, hepatitis C, and H. pylori
Some medications including heparin, quinine, and certain antibiotics

Diagnosis

ITP is primarily a diagnosis of exclusion — meaning doctors rule out other causes of low platelets (such as infections, bone marrow diseases, or medication side effects) before confirming ITP. There is no single definitive test.

Blood Tests

Complete Blood Count (CBC): Confirms low platelet count (typically below 100,000/µL at diagnosis). Other cell lines — red blood cells and white blood cells — are usually normal
Peripheral blood smear: Microscopic examination of blood cells to assess platelet size and morphology and rule out other conditions
Mean Platelet Volume (MPV): Often elevated in ITP, reflecting younger, larger platelets released from the bone marrow in response to platelet destruction

Additional Tests

Depending on clinical suspicion, doctors may also order:

Antinuclear antibody (ANA) test to screen for lupus
HIV and hepatitis C testing
H. pylori testing
Antiphospholipid antibody testing
Thyroid function tests

Bone Marrow Biopsy

A bone marrow biopsy is not routinely required for ITP diagnosis but may be performed in older patients, those with unusual features, or cases that do not respond to standard treatment.

Treatment

Treatment depends on the severity of the platelet count, the presence of bleeding symptoms, and the patient's overall health. Many adults with mild ITP and no significant bleeding may not require immediate treatment — close monitoring is often the initial approach.

Watchful Waiting

In patients with platelet counts above approximately 30,000–50,000/µL and no bleeding symptoms, doctors may recommend monitoring without treatment. Your doctor may choose different thresholds based on your individual situation. Regular CBC checks are used to track trends over time.

First-Line Treatments

Corticosteroids (prednisone or dexamethasone): The most common first treatment. They suppress the immune system's attack on platelets and can raise platelet counts quickly. Long-term use is limited due to side effects.
Intravenous immunoglobulin (IVIG): Used when a rapid increase in platelet count is needed, such as before surgery or during serious bleeding. The effect is temporary.
Anti-D immunoglobulin: Used in Rh-positive patients who have not had a splenectomy. Works by saturating the spleen's clearance capacity.

Second-Line Treatments

For patients whose ITP does not respond to or recurs after first-line treatment:

Splenectomy (surgical removal of the spleen): Removes the primary site of platelet destruction. Effective in about two-thirds of patients but carries surgical risks and requires lifelong infection precautions.
Thrombopoietin receptor agonists (TPO-RAs): Medications such as eltrombopag and romiplostim stimulate the bone marrow to produce more platelets. Used in chronic ITP. These medicines usually need to be taken long term and require routine blood test monitoring.
Rituximab: A monoclonal antibody that depletes B cells responsible for producing platelet antibodies. Used in refractory cases. This treatment affects the immune system and may increase infection risk; your doctor will discuss monitoring and any recommended vaccines before starting.
Fostamatinib: A spleen tyrosine kinase (SYK) inhibitor approved for chronic ITP in adults. Like rituximab, it affects immune function and requires monitoring for infection and other side effects.

ITP in Pregnancy

ITP can complicate pregnancy and requires careful management. Treatment decisions must balance maternal platelet levels against the safety of medications for the developing fetus. Close collaboration between hematology and obstetric teams is essential.

ITP in Children

Most children with acute ITP recover fully within six months without treatment. For children with severe thrombocytopenia or significant bleeding, short courses of corticosteroids or IVIG may be used. Splenectomy is rarely needed in children and is generally deferred unless the condition is chronic and severely symptomatic.

Complications

When platelet counts fall very low — typically below about 20,000–30,000/µL — the risk of serious spontaneous bleeding increases. Counts below about 10,000/µL often prompt immediate treatment, even without active bleeding, depending on your individual situation. Potential complications of untreated or inadequately managed ITP include:

Intracranial hemorrhage (bleeding in the brain) — rare but potentially life-threatening
Severe gastrointestinal bleeding
Heavy menstrual bleeding leading to iron deficiency anemia
Complications from treatment, including infection risk from immunosuppressive therapy or splenectomy

Living With ITP

Many people with ITP lead normal, active lives — particularly those with mild or well-controlled disease. Practical considerations include:

Avoiding medications that impair platelet function, such as aspirin and NSAIDs (ibuprofen, naproxen), unless specifically advised by your doctor
Asking your doctor which activities and sports are safe for you at your usual platelet level
Informing all healthcare providers and dentists of the diagnosis before any procedure
Wearing a medical alert bracelet if platelet counts are severely low
Monitoring for symptoms of bleeding and knowing when to seek urgent care
Attending regular follow-up appointments and CBC checks to track platelet trends over time

Frequently Asked Questions About ITP

Is ITP serious?

ITP ranges from mild to serious depending on the platelet count and presence of bleeding. Many people have mild ITP that requires only monitoring. Severe ITP with very low platelet counts or active bleeding requires prompt treatment. Your doctor will assess your individual risk based on your platelet count, symptoms, and overall health.

Is ITP curable?

In children, acute ITP often resolves completely on its own. In adults, ITP is more often chronic but can go into remission — either spontaneously or with treatment. Splenectomy produces long-term remission in many patients. Even without a complete cure, most people with ITP can manage the condition effectively.

What platelet count is dangerous with ITP?

Platelet counts below about 20,000–30,000/µL are generally considered to carry a higher risk of bleeding. Counts below about 10,000/µL often prompt immediate treatment, even without active bleeding. Your doctor will set individualized thresholds based on your symptoms, bleeding history, and overall medical situation.

Can ITP come back after treatment?

Yes. ITP can relapse after an initial response to treatment. This is why ongoing monitoring is important even after platelet counts normalize. If ITP recurs, the same or different treatments may be used depending on the circumstances.

Does ITP affect other blood test results?

The most consistent finding in ITP is a low platelet count with otherwise normal CBC values. MPV is often elevated because the bone marrow releases larger, younger platelets in response to destruction. Red blood cell and white blood cell counts are typically normal unless bleeding has caused iron deficiency or a secondary condition is present.

Can stress or illness trigger an ITP flare?

Viral infections and physical stress can trigger ITP in predisposed individuals or cause a relapse in people with chronic ITP. This is more commonly seen in children but can occur in adults as well. Staying up to date with vaccinations (where safe given your treatment) and managing other infections promptly can help reduce this risk.

Related Biomarkers

The following blood test markers often appear together on your lab report and can help your doctor understand how ITP is affecting your blood and bone marrow response:

Sources

Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances. 2019;3(23):3829-3866.
Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Advances. 2019;3(22):3780-3817.
Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura. Blood. 2005;106(7):2244-2251.
Cooper N, Ghanima W. Immune Thrombocytopenia. New England Journal of Medicine. 2019;381(10):945-955.
Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children. Blood. 2009;113(11):2386-2393.
Kistangari G, McCrae KR. Immune thrombocytopenia. Hematology/Oncology Clinics of North America. 2013;27(3):495-520.
Abrahamson PE, Hall SA, Feudjo-Tepie M, et al. The incidence of idiopathic thrombocytopenic purpura among adults. Thrombosis and Haemostasis. 2009;101(6):1130-1134.

Article written by: HealthMatters.io Team, reviewed by: HealthMatters Editorial Team Last updated: April 2026